EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A comparative analysis of managed entry agreements in Europe: trends, reporting practices, and financial outcomes

N Franzen, J Vancoppenolle, V P Retèl, S Vogler, W H van Harten

The European Journal of Health Economics · 29.06.2026

DOI: 10.1007/s10198-026-01942-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The European Journal of Health Economics, online erschienen am 29.06.2026. Verfasst von N Franzen und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Netherlands Cancer Institute, PO Box 90203, Amsterdam, 1006 BE, The Netherlands. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Fair Pricing Network.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Payers use Managed Entry Agreements (MEAs) across Europe to manage the financial risks associated with high-cost medicines. While these agreements aim to improve affordability and address uncertainty, their confidential nature raises concerns about transparency, international price referencing, and the validity of economic evaluations. This study examines MEA practices across 13 European countries, analyzing adoption trends, reporting practices, and financial outcomes, and their implications for payer decision-making.

Methods

Data from 2016 to 2022 were collected through (1) mapping national MEA frameworks, stakeholders, and implementation processes; (2) desk research on publicly available activity and financial reports; and (3) validation interviews with public-sector negotiators in each country.

Results

Across 13 countries, 24 MEA frameworks were identified. MEA usage increased substantially, with the highest numbers in 2022 in Germany (356) and France (349), and the largest growth in Belgium (+ 250%) and Norway (+ 227%). Reported expenditure reductions ranged from €0.04 billion (Slovakia) to €5.56 billion (France), with estimated discounts between 14% (Germany) and 54% (Belgium). Reporting remained heterogeneous, with activity data available for fourteen frameworks and financial data for ten. More granular reporting, such as by discount mechanism (Netherlands), therapeutic class (France), or gender (Sweden), was uncommon.

Conclusion

The growing use of MEAs across Europe has widened the gap between list and actual prices. Incomplete and non-standardized reporting reduces the ability to assess financial performance and limits cross-country comparability. Harmonized reporting of aggregated data, without compromising confidentiality, could improve transparency, accountability, and support value-based pricing strategies.

Schlagwörter

Stichwörter der Autor:innen

European health policyHigh-cost medicinesManaged Entry AgreementsPayer decision makingPharmaceutical discountsPharmaceutical pricing transparency

Autor:innen und Institutionen

  • The Netherlands Cancer Institute, PO Box 90203, Amsterdam, 1006 BE, The Netherlands.
  • Erasmus School of Health Policy & Management (ESHPM), Erasmus University, Rotterdam, The Netherlands.
  • The Netherlands Cancer Institute, PO Box 90203, Amsterdam, 1006 BE, The Netherlands. j.vancoppenolle@nki.nl.
  • European Fair Pricing Network, PO Box 90203, Amsterdam, 1006 BE, The Netherlands. j.vancoppenolle@nki.nl.
  • Department of HTSR, University of Twente, PO Box 217, Enschede, 7500 AE, The Netherlands. j.vancoppenolle@nki.nl.
  • WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, Gesundheit Österreich GmbH (GÖG/Austrian National Public Health Institute), Vienna, 1010, Austria.

Förderung

  • European Fair Pricing Network

Zitieren

APA

Franzen, N., Vancoppenolle, J., Retèl, V. P., Vogler, S., & van Harten, W. H. (2026). A comparative analysis of managed entry agreements in Europe: trends, reporting practices, and financial outcomes. The European Journal of Health Economics. https://doi.org/10.1007/s10198-026-01942-3

Vancouver

Franzen N, Vancoppenolle J, Retèl VP, Vogler S, van Harten WH. A comparative analysis of managed entry agreements in Europe: trends, reporting practices, and financial outcomes. The European Journal of Health Economics. 2026. doi:10.1007/s10198-026-01942-3

BibTeX
@article{Franzen2026,
  author = {Franzen, N and Vancoppenolle, J and Retèl, V P and Vogler, S and van Harten, W H},
  title = {A comparative analysis of managed entry agreements in Europe: trends, reporting practices, and financial outcomes},
  journal = {The European Journal of Health Economics},
  year = {2026},
  doi = {10.1007/s10198-026-01942-3}
}
Kostenlos starten →